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Background: The role of annexin II in the development and progression of gastric cancer was explored.
Methods: Real-time PCR was conducted to detect annexin II and S100A6 mRNA expression. Protein expressions of
annexin II and S100A6 were also examined by immunohistochemistry in 436 clinicopathologically characterized
gastric cancer cases.
Results: The expression of annexin II and S100A6 mRNA differ significantly among gastric tumor tissue and
matched non-cancerous gastric mucosa. Protein levels of annexin II and S100A6 were up-regulated in gastric cancer
compared with adjacent non-cancerous tissues. High expression of annexin II correlated with age, location of
tumor, size of tumor, differentiation, histological type, depth of invasion, vessel invasion, lymph node metastasis,
distant metastasis and Tumor, Node, Metastasis (TNM) stage, and also with expression of S100A6. Further
multivariate analysis suggested that expression of annexin II and S100A6 were independent prognostic indicators
for gastric cancer.
Cumulative five-year survival rates of patients with high expression of both annexin II and S100A6 was significantly
lower than those with low expression of both.
Conclusion: Expression of annexin II in gastric cancer was significantly associated with depth of invasion, lymph
node metastasis and distant metastasis, TNM stage, high S100A6 expression, and poor prognosis. Annexin II and
S100A6 proteins could be useful prognostic marker to predict tumor progression and prognosis in gastric cancer.
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Gastric cancer (GC) is the fourth most common malig-
nancy and is ranked as the second most common cause
of cancer-related deaths, with approximately 870, 000
new cases occurring yearly [1]. The geographic distribu-
tion of incidence and mortality of GC varies remarkably
worldwide, with more than one-third of all gastric can-
cer cases occurring in China [2,3]. Different etiologic
factors, such as Helicobacter pylori infection, a diet high
in salt, smoking, and environmental nitrates, have been
associated with the development of GC [4]. Mortality
from GC has declined for the past decades, mainly due
to its early detection by endoscopic techniques, advances
in chemotherapy and surgical techniques [5]. However,* Correspondence: zhaozhongshengzj@gmail.com
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reproduction in any medium, provided the orthe overall five-year survival rate in China is only 40%
[6]. More than 30% of surgical patients are too advanced
to receive curative resection [7]. Therefore, identification
of new diagnostic and prognostic biomarkers for cancer
diagnosis and novel therapeutic targets for treatment are
major goals in this field.
Annexins comprise a multigene family of soluble pro-
teins which interact in a Ca-dependent manner with
phospholipids and intracellular membranes [8]. Annexin
II is an inducible, calcium-dependent phospholipid-bind-
ing protein which has overexpression in a variety of
human malignancies and has emerged as an attractive
candidate receptor for increased plasmin generation on
the tumor cell surface [9-13]. It plays multiple roles in
regulating cellular functions, including angiogenesis,
proliferation, apoptosis, cell migration, invasion and ad-
hesion [13-17]. Frequent partners for the S100 proteins
are members of the annexin protein family [18]. At leastLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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terized, and it has been reported that proteins from the
annexins family and the S100 protein family can form
heterodimer complexes, such as the interaction between
annexin II and S100A6 [19].
We performed the current study to examine expres-
sion of annexin II and S100A6 in surgical specimens of
gastric carcinoma, to explore a possible correlation be-
tween annexin II and S100A6 expression and clinico-
pathological parameters, and to elucidate the clinical/
prognostic value of annexin II and S100A6 in GC.
Methods
Patients and tissue samples
GC tissues were obtained from gastrectomy specimens of
436 patients with primary gastric cancer subjected to cura-
tive surgical resection (median age: 60.0 years; range: 30 to
91 years; 311 men, 125 women) from the Department of
Surgery, Zhejiang Provincial People’s Hospital from Janu-
ary 1998 to January 2004. All tissue samples were forma-
lin-fixed, paraffin-embedded, clinically and
histopathologically diagnosed at the Departments of
Gastrointestinal Surgery and Pathology. The follow-up
deadline was December 2008 and all patients had follow-
up records for more than five years. Survival time was cal-
culated from date of surgery to follow-up deadline or date
of death, which was caused mainly by carcinoma recur-
rence or metastasis. Based on the Lauren classification,
223 cases were intestinal and 213 cases were diffuse gas-
tric cancer. There were 55, 163, and 218 cases from the
cardia, body, and antrum, respectively. According to the
2002 World Health Organization (WHO) histological
classification of gastric carcinoma, there were 326 tubular,
16 papillary, 29 mucinous, 65 signet-ring cell, and 13
highly differentiated, 128 well or moderately differentiated,
293 poorly differentiated, and two undifferentiated adeno-
carcinomas, respectively. Ninety cases were categorized as
stage I, 104 were stage II, 173 were stage III, and 69 were
stage IV. There were 61 cases with distant metastasis. A
total of 92 non-cancerous gastric mucosa were obtained
from gastrectomies of adjacent gastric cancer margins of
>5 cm. Patients with advanced-stage disease underwent
routine chemotherapy after surgery, but no radiation treat-
ment was given to any patients included in our study. We
followed up all patients by consulting their case docu-
ments or by telephone. All of the tissue specimens were
obtained for the present study with patient informed con-
sent and the use of the human specimens was approved
by the Zhejiang Provincial People’s Hospital Institutional
Review Board.
Real-time quantitative PCR
The expressions of annexin II and S100A6 in 40 tumor
tissue samples and matched non-cancerous gastricmucosa were confirmed by real-time PCR. Total RNA was
extracted by Trizol and cDNA was reverse-transcribed by
RevertAid TM reverse transcriptase. Real-time PCR was
carried out using the ABI PRISM 7700 Sequence Detec-
tion System (Applied Biosystems, Hangzhou, Zhejiang,
China), 95°C for ten minutes followed by 40 cycles at 95°C
for 15 seconds and at 60°C for one minute. The primers
for GAPDH (224 bp) were 5′- TGAAGGTCGGAGTC
AACGG -3′ (sense) and 5′- CTGGAAGATGGTGATGG
GATT -3′ (antisense). The primers for annexin II (213 bp)
were 5′- GATGTGAAACACTTTGCTCCT -3′ (sense)
and 5′- ATAGCGACACTTGGATAGGGG -3′ (anti-
sense). The primers for S100A6 (176 bp) were 5′-
GGCTGATGGAAGACTTGGACC -3′ (sense) and 5′-
TTACCCACCACTGGATTTGACTC -3′ (antisense). The
expression of GAPDH was used to normalize that of the
target genes. Each assay was done in triplicate, the average
was calculated, the expression level of annexin II was
expressed as 2–ΔΔCt, where ΔCt=Ct(annexin II)–Ct
(GAPDH), and the expression level of S100A6 was
expressed as 2–ΔΔCt, where ΔCt=Ct(S100A6) – Ct
(GAPDH).
Tissue microarray
The tissue microarray (TMA), containing 528 cases (436
cancer samples and 92 non-cancer tissue samples), was
constructed as described previously [20,21]. Briefly, forma-
lin-fixed, paraffin-embedded archival tissue blocks with
representative regions were selected according to their
matching H & E-stained slides. Core tissue cylinders were
collected from individual paraffin-embedded gastric
tumors (donor blocks) and arranged in recipient paraffin
blocks (tissue array blocks). It has previously been proven
that staining results obtained from different intratumoral
areas in various tumors correlate well, so a core was
sampled in each case. From every archival block, one cy-
linder of 2.0 mm diameter was taken from cancer tissues
of each patient from representative areas and transferred
to paraffin recipient blocks using a trephine. An adequate
case was defined as a tumor occupying >10% of the core
area. Four-micrometer-thick sections were consecutively
incised from the recipient block and transferred to polyly-
sine-coated glass slides. H & E staining was performed on
tissue microarray for confirmation of tumor tissue.
Immunohistochemistry
Immunohistochemistry was performed for each antigen
to study altered protein expression in 92 non-cancerous
gastric tissue controls and 436 gastric cancer tissues [6].
Briefly, TMA slides were baked at 60°C for two hours
followed by deparaffinization in xylene and rehydrated
in graded alcohol.
The sections were submerged into ethylenediaminete-
traacetic acid (EDTA) antigenic retrieval buffer and
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treated with 3% hydrogen peroxide in methanol to quench
endogenous peroxidase activity, followed by incubation
with 0.3% bovine serum albumin to reduce background
non-specific staining. Sections were incubated with rabbit
anti-annexin II (Epitomics Biotechnology Inc, Burlingame,
California, USA), or mouse anti-S100A6 (Santa Cruz Bio-
technology Inc, Delaware Avenue, California, USA), at 4°C
overnight. Negative controls were performed by replace-
ment of the primary antibody with non-reacting anti-
bodies of the same species. After washing, tissue sections
were treated with secondary antibody. Slides were stained
with 3, 3-diaminobenzidine (DAB) and counterstained
with hematoxylin, then dehydrated and mounted. The
membrane with annexin II was stained as buffy, while
S100A6 was stained as buffy in cytoplasm and nuclei.
The degree of immunostaining was scored independ-
ently by two pathologists blinded to the clinical out-
come of the patients, based on the proportion of
positively stained tumor cells and intensity of staining
[22,23]. For each antibody preparation studied, the
staining index was calculated as the product of stain-
ing intensity score and the proportion of positive
tumor cells. The location of immunoreactivity (cyto-
plasmic, nuclear, or combined) was noted and the















































Figure 1 Relative expression of annexin II and S100A6 in the correspo
a. Relative expression of annexin II in the corresponding gastric tumors com
corresponding gastric tumors compared to non-tumour tissues.follows: 0 for <5% positive tumor cells; 1 for 6% to
25% positive tumor cells; 2 for 26% to 50% positive
tumor cells; and 3 for >51% positive tumor cells.
Staining intensity was graded according to the follow-
ing criteria: 0 (no staining); 1 (weak staining = light
yellow); 2 (moderate staining = yellow-brown); and 3
(strong staining = brown). We use this method of as-
sessment to evaluate annexin II and S100A6 expres-
sion in human nontumor mucosa and malignant
lesions by determining the staining index with scores
of 0, 1, 2, 3, 4, 6, or 9. An optimal cut-off value was
identified as: a staining index score of ≥4 was used to
define tumors with high annexin II and S100A6 ex-
pression, and a staining index score of ≤3 was used
to indicate low annexin II and S100A6 expression.
Statistical analysis
Statistical analysis was performed using SPSS13.0 soft-
ware. Measurement data were analyzed using the Stu-
dent’s t test, while categorical data were studied using
the chi-square test or Fisher exact test. The influence of
prognostic factors on tumor-related survival was
assessed by Kaplan-Meier estimates; the log-rank test
was used to compute differences between curves. The
multivariate Cox proportional hazard regression model
was performed to assess prognostic values of protein23 25 27 29 31 33 35 37 39
Normal
Cancer
25 27 29 31 33 35 37 39
Normal
Cancer
nding gastric tumors compared with that in non-tumor tissues.
pared to non-tumor tissues. b. Relative expression of S100A6 in the
Figure 2 Immunohistochemical staining for annexin II in gastric cancer lesions and noncancerous tissues. a, 1 to 3, annexin II negative in
noncancerous tissues; magnifications were × 40, ×100, and × 400, respectively. b, 1 to 3, annexin II was highly expressed in well differentiated
adenocarcinoma; magnifications were × 40, ×100, and × 400, respectively. c, 1 to 3, annexin II was highly expressed in moderately differentiated
adenocarcinoma; magnifications were × 40, ×100,and× 400, respectively. d, 1 to 3, annexin II was highly expressed in poorly differentiated
adenocarcinoma; magnifications were × 40, ×100, and × 400, respectively.
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pression and clinicopathological findings were analyzed
using the Pearson correlation method. A value of P
< 0.05 was considered statistically significant.
Results
mRNA expression of annexin II and S100A6 in gastric
tumor tissue and non-tumor tissue
The mRNA expressions of annexin II and S100A6 in
gastric tumor tissues and corresponding non-tumor tis-
sues were analyzed using qRT-PCR in a total of 40 pairs
of matched tissue specimens. In gastric tumors, the
mRNA expression levels of Annexin II were higher in
cancer tissues (0.037 ± 0.035) than non-tumor tissues
(0.030 ± 0.016, P< 0.05, Figure 1A). The mRNA expres-
sion levels of S100A6 were higher (5.884 ± 6.988) than
non-tumor tissues (2.883 ± 1.687, P< 0.05, Figure 1B).
Expression of annexin II and S100A6 in GC and non-
cancer mucosa
Annexin II protein was detected in 18 of 92 (19.57%)
human non-tumor mucosa; all samples expressed the
protein at low levels. Annexin II protein was detected in175 of 436 (40.14%) human gastric cancer cases. High
expression of annexin II protein was detected in 133
(30.50%) tumors, and low expression was detected in 42
(9.63%) tumors. Annexin II was overexpressed strongly
in the cell membrane of primary cancer and weakly in
the cytoplasm of carcinoma cells (Figure 2). S100A6 pro-
tein was detected in 9 of 92 (9.78%) human nontumor
mucosa; all samples expressed the protein at low levels.
S100A6 protein was detected in 256 of 436 (58.72%)
human gastric cancer cases. High expression of S100A6
protein was detected in 183 (41.97%) tumors and low
expression was detected in 73 (16.74%) tumors. S100A6
was predominantly localized in the cytoplasm, while nu-
clear staining was also detectable in some samples
(Figure 3).Correlation between annexin II and S100A6 and
clinicopathological features
The expression of annexin II correlated with age, loca-
tion of tumor, size of tumor, differentiation, histological
type, depth of invasion, vessel invasion, lymph node me-
tastasis, distant metastasis, and TNM stage (P< 0.05)
but did not correlate with gender (P> 0.05) (Table 1).
Figure 3 Immunohistochemical staining for S100A6 in gastric cancer lesions and noncancerous tissues. a, 1 to 3, S100A6 negative in
noncancerous tissues; magnifications were × 40, ×100, and × 400, respectively. b, 1 to 3, S100A6 was highly expressed in well differentiated
adenocarcinoma; magnifications were × 40, ×100 and× 400, respectively. c, 1 to 3, S100A6 was highly expressed in moderately differentiated
adenocarcinoma; magnifications were × 40, ×100 and× 400, respectively. d, 1 to 3,S100A6 was highly expressed in poorly differentiated
adenocarcinoma; magnifications were × 40, ×100, and × 400,respectively.
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tion, size of tumor, depth of invasion, vessel invasion, lymph
node metastasis, distant metastasis and TNM stage (P
< 0.05), but did not correlate with gender, differentiation or
histological type (P> 0.05) (Table 2). Factors with possible
prognostic effects in gastric carcinoma were analyzed by
Cox regression analysis. Statistical analysis showed that
depth of invasion (P=0.029), lymph node metastasis
(P=0.025), distant metastasis (P=0.016), TNM stage
(P=0.021), expression of annexin II (P= 0.027) and ex-
pression of S100A6 (P= 0.011) were independent prog-
nostic factors in patients with gastric carcinoma.
However, the location of the tumor, tumor size, histo-
logical type, differentiation and vessel invasion had no
prognostic value in our Cox’s proportional hazards re-
gression model. It may relate to sample collection so
it is critical that large sample and well-designed multi-
center studies based on different groups are needed to
confirm our results. We further performed the strati-
fied analysis according to different TNM stages and
the results confirmed that annexin II was an inde-
pendent prognostic factor in patients with gastric car-
cinoma (P= 0.000).Association between expression of annexin II and S100A6
A total of 163 gastric cancer cases had low expression
of both annexin II and S100A6, while 158 gastric
cancer cases had high expression of both annexin II
and S100A6. There was a significant correlation be-
tween annexin II and S100A6 (χ2 = 120.198; P = 0.000)
(Table 1).
Correlation between expression of annexin II and S100A6
and patient prognosis
In stage I, II and III, the five-year survival rates of
patients with high expression of annexin II were all sig-
nificantly lower than in patients with low expression. In
stage I, the cumulative five-year survival rate was 87.2%
in the low-annexin II expression group, but 75.0% in the
high expression group (P= 0.007). In stage II, the cumu-
lative five-year survival rate in the low expression group
(70.4%) was higher than in the high expression group
(45.5%, P= 0.000). In stage III, the cumulative five-year
survival rate was 30.8% in the low expression group,
which was higher than in the high expression group
(17.7%, P= 0.000). In stage IV, annexin II expression did
not correlate with the five-year survival rate and the
Table 1 Relationship of Annexin II expression with
pathological parameters of tumor
Clinical parameters Annexin II
High Low t/χ2 P











Lauren classification 10.277 0.001
Intestinal 142(54.4%) 122(69.7%)
Diffuse 119(45.6%) 53(30.3%)
Histology classification 7.658 0.054
Papillary adenocarcinoma 9(3.4%) 7(4.0%)
Tubular adenocarcinoma 189(72.4%) 137(78.3%)
Mucinous adenocarcinoma 13(5.0%) 16(9.1%)
Signet-ring cell carcinoma 50(19.2%) 15(8.6%)















Lymphatic metastasis 91.842 0.000
No 147(56.3%) 19(10.9%)
Yes 114(43.7%) 156(89.1%)





Table 1 Relationship of Annexin II expression with
pathological parameters of tumor (Continued)






aDistant metastasis refers to cancer that has spread from the original tumor to
distant organs.
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6.2% in the high expression group (P= 0.074). Cumula-
tive five-year survival rates of patients with high expres-
sion of both annexin II and S100A6 was significantly
lower than those with low expression of both (12.7% ver-
sus 38.3%, P= 0.000). (Figure 4)Discussion
Overexpression of the annexin II gene was observed in
human gastric cancer and a recent report found that
annexin II was significantly up-regulated in advanced
gastric cancers and it could contribute to the progres-
sion of gastric carcinoma [24]. The possible clinical sig-
nificance of annexin II has remained unclear in gastric
cancer patients. Therefore, we used immunohistochem-
istry to examine the relationships between annexin II ex-
pression and the clinicopathologic characteristics of
patients with gastric cancer.
The current study showed that annexin II is up-regu-
lated in gastric cancer tissues compared to non-cancer-
ous gastric mucosa. Annexin II levels were found to be
correlated significantly with gastric cancer prognosis. In
addition, high levels of annexin II protein expression in
gastric cancer lesions were closely associated with age,
location of tumor, size of tumor, differentiation, histo-
logical type, depth of invasion, vessel invasion, lymph
node metastasis, distant metastasis, and TNM stage.
Further multivariate analysis suggested that the depth of
invasion, lymph node and distant metastasis, TNM stage,
expression of annexin II, and expression of S100A6 were
independent prognostic indicators for the disease.
Overexpression of annexin II has been associated with
progression and metastasis in hepatocellular carcinoma,
pancreatic cancer, colorectal cancer, lung cancer, breast
cancer and renal cell carcinoma [9,11,25,26]. Conversely,
down-regulation of annexin II has been reported in
prostate carcinoma, esophageal carcinoma and laryngeal
squamous cell carcinoma [27-29]. Therefore, the role of
annexin II in cancer invasion and metastasis remains un-
clear. In hepatocellular carcinoma, annexin II is fre-
quently up-regulated both on the mRNA and the
protein level; hepatitis B virus (HBV)-induced
Table 2 Relationship of S100A6 expression with
pathological parameters of tumor
Clinical parameters S100A6
Negative Positive t/χ2 P











Lauren classification 0.157 0.692
Intestinal 107(40.5%) 157(59.5%)
Diffuse 73(42.4%) 99(57.6%)
Histology classification 7.658 0.054
Papillary adenocarcinoma 9(56.3%) 7(43.7%)
Tubular adenocarcinoma 134(41.1%) 192(58.9%)
Mucinous adenocarcinoma 6(20.7%) 23(79.3%)
Signet-ring cell carcinoma 31(47.7%) 34(52.3%)















Lymphatic metastasis 110.475 0.000
No 121(72.9%) 45(27.1%)
Yes 59(21.9%) 211(78.1%)





Table 2 Relationship of S100A6 expression with
pathological parameters of tumor (Continued)
Distant metastasis 28.936 0.000
No 174(46.4%) 201(53.6%)
Yes 6(9.8%) 55(90.2%)
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pression levels compared to hepatitis C virus (HCV)-
induced hepatocellular carcinoma [9]. The up-regulation
of annexin II expression in pancreatic, colorectal, and
brain tumors was also directly correlated with advanced
clinical stage [30]. Higher annexin II expression was
observed in metastatic breast cancer and colon cancer
cells compared with the non-metastatic cells [11,31]. A
recent study using a proteomic approach investigating
the secretome of the gastric cancer cell line SGC7901
identified annexin A2 as a secreted phosphoprotein [32].
Previous study has indicated that annexin II overexpres-
sion in gastric cancer was more frequently found in in-
testinal-type tumor cases, lymph node metastasis and
venous invasion [24]. Together these studies suggest that
annexin II has potential diagnostic and prognostic value
as a therapeutic target to inhibit cancer progression and
metastasis which needs to be further examined.
Accumulating evidence suggests that interactions be-
tween annexin II and its binding proteins play an im-
portant role in the tumor microenvironment and act
together to enhance cancer metastasis [30]. The list of
annexin II -interacting proteins includes t-PA, p11 pro-
tein, tenascin C and cathepsin B. Annexin and S100 pro-
teins typically form complexes. Annexin II interacts with
S100A4 as well as S100A10 [33]. It is highly expressed
in endothelial cells and is overexpressed in breast and
colon cancer, in which it has been implicated in invasive
behavior. In both B-1 cells and stimulated B-2 cells,
annexin II and S100A6 existed as Ca-dependent com-
plexes [34]. It has also been reported that a strong asso-
ciation is between the presence of annexin II in the
plasma membrane and high levels of cytoplasmic
S100A6 of pancreatic cancer cells [35]. In MKN28 cells
and primary gastric carcinomas, annexin II forms a com-
plex with calpactin I light chain (P11) which belongs to
the S-100 family as EF hand protein and is associated
with cell differentiation, malignant transformation and
cell cycle control [36-38].
To reveal the association among expression of annexin
II and S100A6 in gastric cancer, we also studied the ex-
pression of S100A6 and, as we expected, S100A6 was
up-regulated in gastric cancer tissues compared to nor-
mal gastric tissues. S100A6 protein levels were found to
correlate significantly with the prognosis of gastric can-
cer. S100A6 was found to be widely expressed in gastric
carcinomas and its expression could contribute to the
Figure 4 Kaplan-Meier curves with univariate analyses (log-rank) for patients with simultaneously low annexin II and S100A6
expression versus high annexin II and S100A6 expression tumors in all gastric cancer. The cumulative five-year survival rates of patients
with a simultaneously high expression of annexin II and S100A6 were significantly lower than those in patients with simultaneously low
expression (12.7% versus 38.3%, P= 0.000).
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the prognosis of gastric cancer.
The high level of S100A6 correlated with the expres-
sion of membranous annexin II in patient tumors while
low S100A6 level correlated with a lack expression of
membranous annexin II which suggested that S100A6
may affect the localization of annexin II to membranes
[35]. The interactions between annexin II and S100A6
may play an important role in cancer metastasis and
may provide a novel therapeutic approach for treating a
variety of cancers. We also examined annexin II and
S100A6 expression in gastric cancer specimens and its
correlation with annexin II status. We found a positive
correlation between annexin II and S100A6 expression
with gastric cancer invasion and metastasis, suggesting
that cells with positive annexin II expression may pro-
mote gastric cancer cell invasion and metastasis.Conclusions
In conclusion, our study identified up-regulation of
annexin II and S100A6 in gastric cancer, including an
assessment of annexin II and S100A6 expressions in gas-
tric cancer tissues and noncancerous gastric tissues, sug-
gesting that overexpression of annexin II and S100A6
are common features that may play an important role in
the progression and metastasis of gastric cancer. The
importance of annexin II and S100A6 up-regulation in
gastric cancer is further highlighted by our results that
correlate the unfavorable pathologic parameters of
tumors with poor patient prognosis. These results sug-
gest that annexin II and S100A6 may be useful as clinic-
ally significant prognostic and survival indicators. Our
study has provided a basis for the development of novelbiomarkers for the predicting progression and poor
prognosis with gastric cancer.
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